Clinical and pharmacological outcomes after switching from intravenous to subcutaneous infliximab in chronic inflammatory rheumatic diseases

Fogel, O; Bottois, C; Tourneur, ML; Dauchez, A; D'Alessandro, R; Gaud-Listrat, V; Goulvestre, C; Habhab, K; Souffir, C; Miceli-Richard, C; Moltó, A; Avouac, J; Allanore, Y

doi:10.1016/j.jbspin.2026.106058

Spondyloarthritis & psoriatic arthritis

Clinical and pharmacological outcomes after switching from intravenous to subcutaneous infliximab in chronic inflammatory rheumatic diseases

Joint Bone SpinePublished 24 Mar 2026Prospective observational study

Read the original article ↗PubMed

Cite

Authors' conclusion

These findings support the effectiveness of SC IFX in maintaining disease control in CIR, with a favorable safety profile and significant economic benefits.

Study context

Population: Adults with controlled chronic inflammatory rheumatic diseases (16 axSpA, 5 PsA, 1 unclassified CIR) on intravenous (IV) infliximab, single centre73 eligible
Participants: 22 vs 13

Exposure: Subcutaneous (SC) infliximab after switch from IV infliximab
Enrolledn = 22
Routine caren = 13
Outcome: Retention on SC IFX (enrolled patients)
Follow-up: 6 and 12 months

Methodological detailssingle-center, non-medical switch, Outcomes collected at 3, 6, and 12months; Infliximab (IFX) concentrations and anti-IFX antibodies at baseline, 6months, and 12months

Single-center
Non-medical switch
Outcomes collected at 3, 6, and 12months; IFX concentrations and anti-IFX antibodies at baseline, 6months, and 12months

Main finding

As reported in the abstract

Patients remaining on SC IFX at 6 and 12 months

19 of 22

86%

Observational data: associations, not effects.

Further findings

Mean serum IFX level before scheduled IV infusion (baseline)

Mean serum IFX level: 11±7μg/mL

Mean serum IFX level after switch to SC · 6 months

Mean serum IFX level: 30±17.6μg/mL

Mean serum IFX level after switch to SC · 12 months

Mean serum IFX level: 25.6±13.1μg/mL

Anti-drug antibodies

No anti-drug antibodies detected

Patient satisfaction (out of 10)

Mean satisfaction score: 9.7±0.37

Retention on SC IFX, patients switched in routine care · one year

Remained on SC IFX: 8/13

Annual mean treatment cost per patient, SC IFX vs IV IFX

SC IFX €4,627±23 vs IV IFX €7,456±1,331: P < 0.001

Significantly lower with SC IFX

Safety

Mild adverse events

Patients reporting mild AEs: 6
Pruritus: 1
Injection pain: 2
Injection-site reactions: 4

Resolved in all but one patient by study end

Reference

Authors: Fogel O, Bottois C, Tourneur ML, Dauchez A, D'Alessandro R, Gaud-Listrat V, et al.
All 13 authors
Fogel O, Bottois C, Tourneur ML, Dauchez A, D'Alessandro R, Gaud-Listrat V, Goulvestre C, Habhab K, Souffir C, Miceli-Richard C, Moltó A, Avouac J, Allanore Y
Journal: Joint Bone Spine
Published: 24 Mar 2026
DOI: 10.1016/j.jbspin.2026.106058
PubMed: 41887564

Topic: Spondyloarthritis & psoriatic arthritis
Also indexed: Across rheumatic diseases

Exposure

SC infliximab after switch from IV infliximab (before vs after switch)

Exposure definitions

Enrolled: adults with controlled CIR on stable standard-dose IV IFX (3-5mg/kg every 6-8weeks) for at least three infusions, switched to SC IFX
Routine care: additional patients who switched to SC IFX in routine care, evaluated for treatment retention

Original publication

Clinical and pharmacological outcomes after switching from intravenous to subcutaneous infliximab in chronic inflammatory rheumatic diseases. Joint Bone Spine. Published 24 March 2026. doi:10.1016/j.jbspin.2026.106058

Read the original article ↗

Composed by AI from the published abstract and checked against it. How Briefs are made →